Global Transparency Bulletin

Start adding items to your reading lists:
Save this item to:
This item has been saved to your reading list.

Get the most up-to-date information regarding the evolving nature of spend transparency in the pharmaceutical and life sciences and health industries.

July 2020 Update

United Kingdom

In April, we notified you that the Association of the British Pharmaceutical Industry (ABPI) had released guidance that 2019 data would be submitted and disclosed in the aggregate in an effort to ease the burden on healthcare professionals to review the data during the initial stages of the COVID-19 pandemic.

ABPI has published the 2019 aggregated data, but is now requesting companies "disaggregate" their data and disclose at the individual level. Reports with disaggregated 2019 transfers of value are to be submitted by 31 July 2020. Disaggregated data refers to the individual disclosures for recipients who provided consent for standard disclosure.

The submission portal will be open for companies to submit from Monday 20 July to Friday 31 July at 14:00 GMT.

ABPI also asked companies to confirm that the already published 2019 aggregate data is up to date. The aggregate data will remain published until the official disaggregated data is made available to the public.

June 2020 Update


Recently the National Organization for Medicines (EOF) announced that the deadline for 2019 local EOF disclosure was moved up from September 30, 2020 to June 30, 2020. No change has been noted for the local submission process.


On May 29, 2020, the Colombia Ministry of Health and Social Protection announced that companies will now be able to submit data that was missed from the report due in March 2020. The Registry of Transfers of Value of the Health Sector (“RTVSS”) will be open from June 1-30, 2020 to submit the late data. 

May 2020 Update


In light of COVID-19, the Healthcare Transparency Register Foundation (Stichting Transparantieregister Zorg) has announced that the transparency reporting deadline for 2019 reporting has been extended from 1 June 2020 to 15 June 2020. No change has been noted for the submission process to the transparency register.

April 2020 Update

United Kingdom

The Association of the British Pharmaceutical Industry (ABPI) hosted a webcast to discuss the latest guidance for 2019 transparency disclosures. Their decision has been made to only publish aggregate data on the Disclosure UK portal. Companies are advised to submit all healthcare professional (HCP) and healthcare organization (HCO) data in aggregate, along with research and development. The only exception is joint working arrangements, which will be provided in methodological notes. ABPI will provide an amended, temporary data template for companies to submit 2019 data.

Here are next steps for your consideration:

  • Complete a temporary, aggregated 2019 data template provided by ABPI
  • Submit the aggregated 2019 data template to Disclosure UK portal in May or June 2020 (exact dates to be communicated by ABPI)
  • Update your 2019 methodological notes to account for the latest guidance. ABPI will share a sample excerpt that provides details on the circumstances surrounding COVID-19 and how to include joint working payments
  • Continue to respond and resolve inquiries raised for any historic data from 2016-2018 in the Disclosure UK portal (noting that 2016 data will be removed from the portal 30 June, 2020). For any data amendments, you can continue to submit as standard. However, ABPI may not publish until it is deemed appropriate
  • Keep your original, disaggregated 2019 data template and original methodological notes, as submission to the Disclosure UK portal is expected later this year
  • If your company decides to move forward to publish 2019 data on company website: 
    • Do not contact HCPs/HCOs, unless required to contractually or by company standard operating procedure
    • It is recommended to remove email addresses or third party IDs from the template disclosed


Recently, the Irish Pharmaceutical Healthcare Association (IPHA) shared more information regarding consent trends and reporting in light of COVID-19. Guidance shared from IPHA differs from the direction ABPI has taken by asking companies to continue individual disclosure where appropriate consent has been captured. Therefore, no changes are asked to be made due to COVID-19 for 2019 data.

Here are the key takeaways:

  • Consent rates have risen consistently year over year
  • Companies should continue to report recipients on the individual level, where appropriate consent has been captured, for 2019 data
    • Encourage companies not to aggregate but to aim for high levels of individual level disclosure to maintain transparency in society
    • There are no restrictions on sending reminder letters to HCPs
  • Disclosure reports should include rounded transfer of value amounts (e.g., no decimals) for 2019 data and onwards

How PwC can help:

  • Provide experienced resources to support transparency program
  • Deliver hands on, fast approach to tackle data quality issues
  • Generate automated transparency reports based on your company’s unique data inputs and customized business rules
  • Coordinate with Third Party Vendors and review accuracy/completeness of data
  • Strategize and implement process improvements to reduce cost and maximize efficiencies
  • Provide technology through our latest PwC product offering Transparency Hub - a true all-in-one, cloud-based solution for global transparency reporting.

Ready to learn more?

PwC has a team of experienced compliance professionals ready to support your transparency program needs!

Feeling overwhelmed with activities leading as we enter into the critical reporting season? We hear you! PwC has a global team of trusted advisors that can support you and your team navigate through the complexity of reporting. Please reach out to us to start the conversation.

This content is for general information purposes only and should not be used as a substitute for consultation with professional advisors.

Contact us

David Wysocky

Principal, Pharmaceutical and Life Sciences Transparency Leader, PwC US

Nate Lebowitz

Director, Requirements Lead, PwC US

Tim Canonico

Partner, Pharmaceutical & Life Sciences, PwC US

Follow us